Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Change in Accured Expenses (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Change in Accured Expenses for 7 consecutive years, with -$536000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 164.97% year-over-year to -$536000.0, compared with a TTM value of -$33000.0 through Dec 2025, up 97.54%, and an annual FY2025 reading of -$33000.0, up 97.54% over the prior year.
  • Change in Accured Expenses was -$536000.0 for Q4 2025 at aTYR PHARMA, down from $18000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $4.8 million in Q2 2025 and bottomed at -$4.3 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $433900.0, with a median of $198000.0 recorded in 2021.
  • The sharpest move saw Change in Accured Expenses skyrocketed 935.0% in 2022, then plummeted 11097.37% in 2024.
  • Year by year, Change in Accured Expenses stood at $180000.0 in 2021, then surged by 935.0% to $1.9 million in 2022, then soared by 81.86% to $3.4 million in 2023, then crashed by 75.65% to $825000.0 in 2024, then plummeted by 164.97% to -$536000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for ATYR at -$536000.0 in Q4 2025, $18000.0 in Q3 2025, and $4.8 million in Q2 2025.